<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Ceribell, Inc — News on 6ix</title>
<link>https://6ix.com/company/ceribell-inc</link>
<description>Latest news and press releases for Ceribell, Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 29 Apr 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/ceribell-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835529278dffbe2df0e8191.webp</url>
<title>Ceribell, Inc</title>
<link>https://6ix.com/company/ceribell-inc</link>
</image>
<item>
<title>Ceribell to Participate in the Bank of America Securities 2026 Health Care Conference</title>
<link>https://6ix.com/company/ceribell-inc/news/ceribell-to-participate-in-the-bank-of-america-securities-2026-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/ceribell-inc/news/ceribell-to-participate-in-the-bank-of-america-securities-2026-health-care-conference</guid>
<pubDate>Wed, 29 Apr 2026 20:05:00 GMT</pubDate>
<description>SUNNYVALE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, and Scott Blumberg, CFO, will participate in a fireside chat at the upcoming Bank of America Securities 2026 Health Care Conference. The fireside chat will take place on Wednesday, May 13, 2026, at 3:40 p.m. Pac</description>
</item>
<item>
<title>Ceribell to Report First Quarter 2026 Financial Results on May 11, 2026</title>
<link>https://6ix.com/company/ceribell-inc/news/ceribell-to-report-first-quarter-2026-financial-results-on-may-11-2026</link>
<guid isPermaLink="true">https://6ix.com/company/ceribell-inc/news/ceribell-to-report-first-quarter-2026-financial-results-on-may-11-2026</guid>
<pubDate>Mon, 20 Apr 2026 20:05:00 GMT</pubDate>
<description>SUNNYVALE, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the first quarter of 2026 after the close of trading on Monday, May 11, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on May 11, 2026.</description>
</item>
<item>
<title>Ceribell Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/ceribell-inc/news/ceribell-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/ceribell-inc/news/ceribell-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Tue, 24 Feb 2026 21:05:00 GMT</pubDate>
<description>SUNNYVALE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 & Recent Highlights Reported total revenue of $24.8 million in the fourth quarter of 2025, a 34% increase compared to the same period in 2024Delivered total</description>
</item>
<item>
<title>Ceribell to Participate in Upcoming March Investor Conferences</title>
<link>https://6ix.com/company/ceribell-inc/news/ceribell-to-participate-in-upcoming-march-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/ceribell-inc/news/ceribell-to-participate-in-upcoming-march-investor-conferences</guid>
<pubDate>Wed, 18 Feb 2026 21:05:00 GMT</pubDate>
<description>SUNNYVALE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the company will be participating in two upcoming investor conferences. Scott Blumberg, CFO, will present at the upcoming Raymond James 47th Annual Institutional Investors Conference on Monday, March 2, 2026, at 1:00 p.m. Pacific Standard Time / 4:00 p.m.</description>
</item>
<item>
<title>Ceribell to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026</title>
<link>https://6ix.com/company/ceribell-inc/news/ceribell-report-fourth-quarter-full-210500906</link>
<guid isPermaLink="true">https://6ix.com/company/ceribell-inc/news/ceribell-report-fourth-quarter-full-210500906</guid>
<pubDate>Tue, 10 Feb 2026 21:05:00 GMT</pubDate>
<description>SUNNYVALE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the fourth quarter and full year of 2025 after the close of trading on Tuesday, February 24, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m.</description>
</item>
<item>
<title>Ceribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution</title>
<link>https://6ix.com/company/ceribell-inc/news/ceribell-receives-fda-breakthrough-device-130000888</link>
<guid isPermaLink="true">https://6ix.com/company/ceribell-inc/news/ceribell-receives-fda-breakthrough-device-130000888</guid>
<pubDate>Mon, 05 Jan 2026 13:00:00 GMT</pubDate>
<description>Clearance would position the Ceribell System as the first and only point-of-care electroencephalography (EEG) technology to aid in detection and monitoring of Large Vessel Occlusion (LVO) stroke in the hospital settingSUNNYVALE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U.S. Food and Drug Administr</description>
</item>
<item>
<title>Ceribell to Participate in the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/ceribell-inc/news/ceribell-participate-44th-annual-j-210500103</link>
<guid isPermaLink="true">https://6ix.com/company/ceribell-inc/news/ceribell-participate-44th-annual-j-210500103</guid>
<pubDate>Tue, 30 Dec 2025 21:05:00 GMT</pubDate>
<description>SUNNYVALE, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation will take place on Monday, January 12, 2026, at 9:00 am Pacific Standard Time / 12:00 pm Eastern Stand</description>
</item>
<item>
<title>Ceribell Receives FDA 510(k) Clearance for First-of-its-Kind Delirium Monitoring Solution</title>
<link>https://6ix.com/company/ceribell-inc/news/ceribell-receives-fda-510-k-130000857</link>
<guid isPermaLink="true">https://6ix.com/company/ceribell-inc/news/ceribell-receives-fda-510-k-130000857</guid>
<pubDate>Tue, 09 Dec 2025 13:00:00 GMT</pubDate>
<description>Novel technology paves the way for use of the company's industry-leading point-of-care electroencephalography (EEG) system to address long unmet need in delirium monitoringSUNNYVALE, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for i</description>
</item>
<item>
<title>Ceribell Receives FDA 510(k) Clearance for Use of ClarityⓇ Algorithm for Neonates</title>
<link>https://6ix.com/company/ceribell-inc/news/ceribell-receives-fda-510-k-130000246</link>
<guid isPermaLink="true">https://6ix.com/company/ceribell-inc/news/ceribell-receives-fda-510-k-130000246</guid>
<pubDate>Mon, 24 Nov 2025 13:00:00 GMT</pubDate>
<description>Becomes the first and only FDA-cleared seizure detection algorithm for pre-term neonates through adults enabling rapid bedside detection, diagnosis, and treatment of non-convulsive seizures SUNNYVALE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(</description>
</item>
<item>
<title>Ceribell to Participate in the Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/ceribell-inc/news/ceribell-participate-piper-sandler-37th-210500206</link>
<guid isPermaLink="true">https://6ix.com/company/ceribell-inc/news/ceribell-participate-piper-sandler-37th-210500206</guid>
<pubDate>Wed, 19 Nov 2025 21:05:00 GMT</pubDate>
<description>SUNNYVALE, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming Piper Sandler 37th Annual Healthcare Conference in New York. The presentation will take place on Wednesday, December 3, 2025, at 6:10 a.m. Pacific Standard Time / 9:10 a.m. Eastern St</description>
</item>
<item>
<title>Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum</title>
<link>https://6ix.com/company/ceribell-inc/news/ceribell-participate-canaccord-genuity-medtech-210500949</link>
<guid isPermaLink="true">https://6ix.com/company/ceribell-inc/news/ceribell-participate-canaccord-genuity-medtech-210500949</guid>
<pubDate>Thu, 06 Nov 2025 21:05:00 GMT</pubDate>
<description>SUNNYVALE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Scott Blumberg, CFO, will participate in a fireside chat at the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York. The fireside chat will take place on Thursday, November 20, 2025, at 5:30 a.m. Pacific St</description>
</item>
<item>
<title>Ceribell Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/ceribell-inc/news/ceribell-reports-third-quarter-2025-210500123</link>
<guid isPermaLink="true">https://6ix.com/company/ceribell-inc/news/ceribell-reports-third-quarter-2025-210500123</guid>
<pubDate>Tue, 04 Nov 2025 21:05:00 GMT</pubDate>
<description>SUNNYVALE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended September 30, 2025. Third Quarter 2025 & Recent Highlights Reported total revenue of $22.6 million in the third quarter of 2025, a 31% increase compared to the same period in 2024Achieved gross margin of 88% compared</description>
</item>
<item>
<title>Ceribell to Report Third Quarter 2025 Financial Results on November 4, 2025</title>
<link>https://6ix.com/company/ceribell-inc/news/ceribell-report-third-quarter-2025-200500467</link>
<guid isPermaLink="true">https://6ix.com/company/ceribell-inc/news/ceribell-report-third-quarter-2025-200500467</guid>
<pubDate>Tue, 21 Oct 2025 20:05:00 GMT</pubDate>
<description>SUNNYVALE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the third quarter of 2025 after the close of trading on Tuesday, November 4, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on November</description>
</item>
<item>
<title>Medtech Leader Erica Rogers Joins Ceribell Board of Directors</title>
<link>https://6ix.com/company/ceribell-inc/news/medtech-leader-erica-rogers-joins-120000905</link>
<guid isPermaLink="true">https://6ix.com/company/ceribell-inc/news/medtech-leader-erica-rogers-joins-120000905</guid>
<pubDate>Mon, 22 Sep 2025 12:00:00 GMT</pubDate>
<description>Accomplished innovator and healthcare executive brings proven strategic leadership and expertise in scaling high-growth healthcare companiesSUNNYVALE, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the appointment of Erica Rogers to its Board of Directors. Ms. Rogers brings over three decades o</description>
</item>
<item>
<title>Ceribell Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/ceribell-inc/news/ceribell-reports-second-quarter-2025-200500034</link>
<guid isPermaLink="true">https://6ix.com/company/ceribell-inc/news/ceribell-reports-second-quarter-2025-200500034</guid>
<pubDate>Tue, 05 Aug 2025 20:05:00 GMT</pubDate>
<description>SUNNYVALE, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended June 30, 2025. Second Quarter 2025 & Recent Highlights Reported total revenue of $21.2 million in the second quarter of 2025, a 38% increase compared to the same period in 2024Achieved gross margin of 88% in the seco</description>
</item>
<item>
<title>Ceribell to Participate in the Canaccord Genuity 45th Annual Growth Conference</title>
<link>https://6ix.com/company/ceribell-inc/news/ceribell-participate-canaccord-genuity-45th-200500895</link>
<guid isPermaLink="true">https://6ix.com/company/ceribell-inc/news/ceribell-participate-canaccord-genuity-45th-200500895</guid>
<pubDate>Tue, 29 Jul 2025 20:05:00 GMT</pubDate>
<description>SUNNYVALE, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming Canaccord Genuity 45th Annual Growth Conference. The presentation will take place on Tuesday, August 12, 2025, at 11:00 a.m. Pacific Standard Time / 2:00 p.m. Eastern Standard Time. E</description>
</item>
<item>
<title>Ceribell to Report Second Quarter 2025 Financial Results on August 5, 2025</title>
<link>https://6ix.com/company/ceribell-inc/news/ceribell-report-second-quarter-2025-200500703</link>
<guid isPermaLink="true">https://6ix.com/company/ceribell-inc/news/ceribell-report-second-quarter-2025-200500703</guid>
<pubDate>Tue, 22 Jul 2025 20:05:00 GMT</pubDate>
<description>SUNNYVALE, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the second quarter of 2025 after the close of trading on Tuesday, August 5, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on August 5,</description>
</item>
<item>
<title>Ceribell Files Complaints Against Natus Medical Incorporated with the U.S. International Trade Commission and Federal Court in Delaware</title>
<link>https://6ix.com/company/ceribell-inc/news/ceribell-files-complaints-against-natus-204200327</link>
<guid isPermaLink="true">https://6ix.com/company/ceribell-inc/news/ceribell-files-complaints-against-natus-204200327</guid>
<pubDate>Mon, 07 Jul 2025 20:42:00 GMT</pubDate>
<description>Complaints Assert Infringement of Patents Related to Point-of-Care Electroencephalography (EEG) TechnologySUNNYVALE, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a leading medical technology company transforming the diagnosis and management of patients with serious neurological conditions, announced today that it filed complaints against Natus Medical Incorporated and related subsidiaries (“Natus”), alleging patent infringement and unfair competition. A c</description>
</item>
<item>
<title>Ceribell to Participate in the William Blair 45th Annual Growth Stock Conference</title>
<link>https://6ix.com/company/ceribell-inc/news/ceribell-participate-william-blair-45th-200500008</link>
<guid isPermaLink="true">https://6ix.com/company/ceribell-inc/news/ceribell-participate-william-blair-45th-200500008</guid>
<pubDate>Tue, 20 May 2025 20:05:00 GMT</pubDate>
<description>SUNNYVALE, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming William Blair 45th Annual Growth Stock Conference. The presentation will take place on Tuesday, June 3, 2025, at 7:20 a.m. Pacific Standard Time / 9:20 a.m. Central Standard Time. Even</description>
</item>
<item>
<title>Ceribell Reports First Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/ceribell-inc/news/ceribell-reports-first-quarter-2025-200500259</link>
<guid isPermaLink="true">https://6ix.com/company/ceribell-inc/news/ceribell-reports-first-quarter-2025-200500259</guid>
<pubDate>Thu, 08 May 2025 20:05:00 GMT</pubDate>
<description>SUNNYVALE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended March 31, 2025. First Quarter 2025 & Recent Highlights Reported total revenue of $20.5 million in the first quarter of 2025, a 42% increase compared to the same period in 2024Ended the quarter with 558 total active ac</description>
</item>
</channel>
</rss>